K-V Pharmaceutical Company has appointed Ana Stancic to the company's board of directors as a new independent member. She replaces Terry Hatfield, whose resignation from the board was effective upon Stancic's appointment.

Stancic brings to the board extensive knowledge and experience in long- and short-term strategic planning, and the development and execution of goals and objectives to maximize shareholder value. Currently, she also is a board member for Champions Biotechnology, serves on its executive committee, and acts as chair of its audit committee.

Prior to joining the Board of Champions Biotechnology, Stancic served as the CFO of Aureon Laboratories, a privately held life science company, where her responsibilities included finance, treasury, and tax compliance. With two decades of diversified pharmaceutical business experience under her belt, Stancic has also served as executive vice president and CFO of Omrix Biopharmaceuticals, prior to its acquisition by Johnson & Johnson; senior vice president and principal financial officer of ImClone Systems, prior to its acquisition by Eli Lilly & Company; vice president and corporate controller of Savient Pharmaceuticals; vice president and chief accounting officer of Ogden Corporation; CFO, Northeast Region of Omnicare; and senior manager-business assurance with PricewaterhouseCoopers.

Topics